한글목차

의약품 수탁제조 업계의 M&A에 대해 조사했으며, M&A의 개요 및 CDMO의 실적 상세, M&A와 사모펀드 투자의 분석 등을 제공하고 있습니다.

목차

• 개요
• 참여 기업
• 기술 상황 개요
• 거래 유형
• 동향
• 산업 분석
• 목적과 조사 방법
• M&A 활동의 개요(2023년)
• 타깃 특징
• 인수 기업의 특징
• 지역
• 주요 인수 기업
• Biosynth가 Celares와 Pepceuticals를 인수
• IPCA Laboratories가 Unichem에 투자
• 타깃 부문 클로즈 업
• 멀티
• API - 소분자
• API - 생물학적
• 상업 투약 제조
• 거래 어드바이저
• 주요 파이낸셜 어드바이저
• 주요 법률 어드바이저
• 평가
• 시설 인수
• 그것이 의미하는 것
• 의약품 부족으로 인해 저기술 저분자 거래가 촉진된다.
• 타깃이 되는 멀티 서비스·주사제 제조업체
• Catalent 인수는 제약 산업과 CMO 산업의 상황을 일변시킨다.
• 바이오의약품 인수는 2023년에 감소했으나, BIOSECURE Act에 의해 제조 계약이 복잡화하고 있음에도 불구하고 여전히 강한 관심이 남아 있다.
• 사모펀드 투자는 감소
• M&A 전망
• API - 생물학적 표적
• API - 세포·유전자 치료 표적
• 밸류체인
• 기업

부록

영문목차

This report is the fifth edition of our analysis of mergers and acquisitions in the pharmaceutical contract manufacturing industry. PharmSource is the most definitive, trustworthy source of strategic insight on this topic in the bio/pharmaceutical realm.

Scope

This 53-page report gives important, expert insight you won't find in any other source. 12 tables and 19 figures throughout the report illustrate major points and trends. This report is required reading for -

• CMOs: market trends, strategic planning, competitive intelligence, performance benchmarking
• Bio/Pharma: supplier performance benchmarking, market trends, competitive intelligence
• Private equity and stock analysts: target identification and analysis, portfolio company performance benchmarking

Reasons to Buy

• Overview of M&A in the Pharma CMO Industry
• Detailed view of CDMO performance by number of deals, based on GlobalData's Deals database
• Analysis of M&A and private equity investment by target's specific manufacturing services

Table of Contents

Table of Contents

• Executive Summary
• Players
• Technology Briefing
• Deal types.
• Trends
• Industry Analysis
• Objectives and methodology
• Overview of M&A activity 2023
• Target characteristics
• Acquirer characteristics
• Geography
• Top acquirers
• Biosynth acquires Celares and Pepceuticals
• IPCA Laboratories invests in Unichem
• Target segment close-ups
• Multi
• API-small molecule
• API-biologic
• Commercial dose manufacturing
• Deal advisors.
• Top financial advisors
• Top legal advisors
• Valuations
• Facility acquisitions
• What it means
• Drug shortages drive low-tech small molecule deals.
• Multi-service and injectable manufacturers targeted
• Catalent acquisition shakes up pharma and CMO landscape.
• Biologic acquisitions decreased in 2023 but strong interest remains, despite BIOSECURE Act complicating manufacturing agreements
• Private equity investments declined
• The outlook for M&A
• API - biologic targets
• API - cell and gene therapy targets
• Value Chain
• Companies

Appendix

• Methodology
• Bibliography
• Primary research - key opinion leaders
• Further reading
• About the Authors